Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -369.83M | -328.25M | -298.41M | -277.91M | -258.54M |
| Total Depreciation and Amortization | 3.44M | 3.24M | 2.79M | 2.26M | 1.76M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.99M | 64.04M | 58.02M | 55.60M | 51.20M |
| Change in Net Operating Assets | -5.40M | -2.62M | 9.61M | 18.22M | 25.22M |
| Cash from Operations | -301.80M | -263.59M | -228.00M | -201.84M | -180.35M |
| Capital Expenditure | -6.00M | -3.75M | -3.84M | -3.75M | -6.72M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -563.50M | -657.34M | -570.97M | -116.29M | -327.21M |
| Cash from Investing | -569.49M | -661.09M | -574.82M | -120.04M | -333.94M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 656.50M | 654.13M | 1.06B | 513.24M | 813.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -33.65M | -30.80M | -48.10M | -16.89M | -36.84M |
| Cash from Financing | 622.86M | 623.33M | 1.01B | 496.35M | 776.90M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -248.44M | -301.36M | 209.65M | 174.47M | 262.61M |